---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-079684"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:32:10.271030+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Iovance reports ~$317M cash as of June 30; authorized shares increased to 500M

## Summary
- Preliminary cash, equivalents, short-term investments, and restricted cash ~$317M as of June 30, 2023 (unaudited).
- Stockholders approved increase in authorized common stock from 300M to 500M at June 6 annual meeting; certificate filed June 9.
- The cash estimate is subject to change upon completion of quarter-end closing procedures.

## SEC filing metadata
- accession: 0001104659-23-079684
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/0001104659-23-079684-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465923079684/tm2320915d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-079684
- JSON: https://secwatch.observer/filing/0001104659-23-079684.json
- Plain text: https://secwatch.observer/filing/0001104659-23-079684.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.